Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure |
| |
| Authors: | Javaid Iqbal Yasir Parviz Bertram Pitt John Newell‐Price Abdallah Al‐Mohammad Faiez Zannad |
| |
| Affiliation: | 1. Department of Cardiovascular Science at the University of Sheffield and Cardiology Department at Sheffield Teaching Hospitals NHS Trust, , Sheffield, UK;2. Cardiovascular Centre, University of Michigan, , Ann Arbor, MI, USA;3. Department of Human Metabolism at the University of Sheffield and Endocrinology Department at Sheffield Teaching Hospitals NHS Trust, , Sheffield, UK;4. INSERM, Centre d'Investigation Clinique and Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Université de Lorraine, , Nancy, France |
| |
| Abstract: | Clinical trials have demonstrated morbidity and mortality benefits of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. These studies have used either spironolactone or eplerenone as the MRA. It is generally believed that these two agents have the same effects, and the data from studies using one drug could be extrapolated for the other. National and international guidelines do not generally discriminate between spironolactone and eplerenone, but strongly recommend using an MRA for patients with heart failure due to LV systolic dysfunction and post‐infarct LV systolic dysfunction. There are no major clinical trials directly comparing the efficacy of these two drugs. This article aims to compare the pharmacokinetics and pharmacodynamics of spironolactone and eplerenone, and to analyse the available data for their cardiovascular indications and adverse effects. We have also addressed the role of special circumstances including co‐morbidities, concomitant drug therapy, cost, and licensing restrictions in choosing an appropriate MRA for a particular patient, thus combining an evidence‐based approach with personalized medicine. |
| |
| Keywords: | Aldosterone Spironolactone Eplerenone Heart failure |
|
|
